Restoring the antigen-specific immune tolerance offers the most promising strategy for treating autoimmune diseases at their root cause, without inducing general immunosuppression. NIMVEC’s non-immunogenic SV40 vector platform is designed to reeducate the patient’s immune system by eliminating only the autoreactive cells, providing a novel approach to developing disease-modifying therapies for Type 1 Diabetes and other autoimmune disorders where conventional treatments only manage symptoms.
